Top View
- UNIVERSITY of CALIFORNIA Los Angeles Disease
- 5.01.570 Pharmacologic Treatment of Duchenne Muscular Dystrophy
- Antisense Oligonucleotides: a Unique Treatment Approach
- And Golodirsen-Treated Duchenne Muscular Dystrophy Patients
- Eteplirsen for Duchenne Muscular Dystrophy
- Medications for Duchenne Muscular Dystrophy SERVICE: Casimersen
- ― D13 - 1 ― 医学中央雑誌刊行会・医学用語シソーラス 第9版( 2019) カテゴリー別リスト
- Application Number
- ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2018
- Procedures, Programs and Drugs You Must Precertify
- Nanomedicine for Gene Delivery and Drug Repurposing in the Treatment of Muscular Dystrophies
- ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
- EXONDYS 51 (Eteplirsen) Injection, for Intravenous Use • 100 Mg/2 Ml (50 Mg/Ml) in Single-Dose Vial (3) Initial U.S
- Current Translational Research and Murine Models for Duchenne Muscular Dystrophy
- Services and Medicare Part B Drugs These Services May Or May Not Be Covered by Your Healthpartners Plan
- Deflazacort, Eteplirsen, and Golodirsen for Duchenne Muscular Dystrophy: Effectiveness and Value
- Overview of Gene Therapy in Spinal Muscular Atrophy and Duchenne
- (Golodirsen), Exondys 51 (Eteplirsen), Viltepso (Viltolarsen) MB2118
- Exondys, Through the Centralised Procedure Falling Within the Article 3(1) and Point 4 of Annex of Regulation (EC) No 726/2004
- 213026Orig1s000
- Therapeutic Strategies for Duchenne Muscular Dystrophy: an Update
- Phpprime Prior Auth Drug List
- Therapeutic Update on Neuromuscular Disorders SMA and DMD Conference Highlights from 2018 Disclaimer
- Authorizations for Medical Drugs
- CCS NL 02-0321 Treatment Of
- Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial Craig Mcdonald,1 Perry Shieh,2 Hoda Z
- Services and Medicare Part B Drugs These Services May Or May Not Be Covered by Your Healthpartners Plan
- Antisense Oligonucleotides: an Emerging Area in Drug Discovery and Development
- Eteplirsen for Duchenne Muscular Dystrophy in Patients Amenable to Exon 51 Skipping
- Amondys 45™ (Casimersen) (For Louisiana Only) Policy Number: CSLA2021D00105A Effective Date: Instructions for Use
- Department of Health Care Services
- Pipeline Report Report
- Nusinersen Use in Spinal Muscular Atrophy Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology
- Medical Policy Reference List (Commercial) 2021 Benefit Procedure Code List Updated August 2021
- A New Era in the Management of Neuromuscular Disorders in Children and Adolescents
- Pipeline Highlights 2016: Focus on Duchenne Muscular Dystrophy
- RNA-Targeted Therapies and High-Throughput Screening Methods
- 212154Orig1s000
- Exondys 51® (Eteplirsen)
- 1 Glycans and Glycoproteins As Biomarkers and Treatments For
- Exon Skipping for Duchenne Muscular Dystrophy
- Realizing the Potential of Rna-Based Technology
- Exondys 51™ (Eteplirsen)
- Virginia DUR Quarterly Newsletter
- Emerging Drugs for Duchenne Muscular Dystrophy
- Investigating the Brain in Mouse Models of Duchenne Muscular Dystrophy
- Specialty Pharmacy Infusion Site of Care Benefit Preauthorization Drug List
- Riv ACTA Myo 1 2018.Pdf
- FDA Fosters Development of Therapies for Children with Rare Diseases
- Providers | Gene Based Therapy for Duchenne Muscular Dystrophy Policy